Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses human genetics to develop small molecule precision medicines for kidney and metabolic diseases. The company uses its Compass platform to identify and characterize genetic variations linked to health and disease, and then determines how these variations contribute to disease risk or protection in specific patient groups through a process called variant functionalization. The Compass platform is designed to inform all stages of drug discovery, development, and clinical trial design. Maze Therapeutics, Inc. is currently advancing two wholly-owned clinical programs: MZE829 and MZE782. Its most advanced program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1 (APOL1) for treating APOL1-mediated kidney disease (AMKD), a genetically defined type of chronic kidney disease (CKD) that currently has no approved treatment. In October 2024, the company reported results from its Phase 1 clinical trial of MZE829, which enrolled 111 healthy adult volunteers. MZE829 was well tolerated and showed dose-proportional pharmacokinetics (PK). A Phase 2 trial of MZE829 began in November 2024, with the first patient dosed in February 2025. In March 2026, positive topline clinical proof of concept data were reported from this open-label study, which enrolled 15 patients. All 15 patients were included in a safety and tolerability analysis, and 12 were evaluable for efficacy. MZE829 was well tolerated, and treatment resulted in a mean reduction in urinary albumin-to-creatinine ratio (uACR) of 35.6% at week 12 in evaluable patients with broad AMKD, with 50% of these patients achieving at least a 30% reduction in uACR. In a subset of patients with focal segmental glomerulosclerosis (FSGS), the mean uACR reduction was 61.8%. Treatment of non-diabetic AMKD patients with MZE829 led to a mean reduction from baseline uACR of 48.6%. The company plans to continue enrollment in the Phase 2 trial and advance MZE829 into a pivotal development program.